Back to News
Market Impact: 0.4

Validea Detailed Fundamental Analysis

LLYNDAQ
Company FundamentalsAnalyst InsightsHealthcare & Biotech
Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates that Eli Lilly (LLY) receives a 77% rating based on their P/B Growth Investor model, which is based on the strategy of Partha Mohanram and focuses on low book-to-market stocks with sustained growth characteristics; the model shows strengths in book/market ratio, return on assets, and cash flow metrics, but weaknesses in capital expenditures to assets and research and development to assets.

Analysis

Eli Lilly and Co. (LLY) garners a 77% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, which targets low book-to-market stocks exhibiting traits of sustained future growth. This score approaches the 80% threshold indicative of model interest. LLY demonstrates fundamental strengths by passing criteria for its book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, sales variance, and advertising to assets. These passes suggest sound financial health, operational consistency, and effective marketing. However, the model flags weaknesses as LLY fails the tests for capital expenditures to assets and research and development to assets. These particular failures, within the context of a growth-focused strategy, may indicate that current levels of investment in fixed assets and R&D, relative to the company's asset base, do not align with the model's ideal profile for aggressively reinvesting for future growth, warranting closer scrutiny of its capital allocation for long-term expansion.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

moderately positive

Sentiment Score

0.40

Ticker Sentiment

LLY0.50
NDAQ0.00

Key Decisions for Investors

  • Investors should acknowledge Eli Lilly's robust performance in core profitability and cash generation metrics as identified by the Partha Mohanram model, while noting the 77% score indicates a moderate, not compelling, fit with this specific growth strategy's criteria.
  • A deeper dive into LLY's capital expenditure and R&D spending relative to its asset base is advisable to understand the context behind these 'fail' ratings and their potential impact on sustaining long-term growth.
  • Given the mixed signals from this specific model—strong fundamental passes offset by concerns in capital and R&D investment ratios—investors might consider LLY's profile in conjunction with other analytical tools and broader market assessments before adjusting positions significantly based solely on this report.